The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Sharp & Dohme
 
Employment - Sharp & Dohme
Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.
 
Yung-Jue Bang
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genexine; Green Cross; Hanmi; Lilly; Merck Serono; MSD Oncology; Novartis; Samyang; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Makoto Ueno
Honoraria - AstraZeneca; Lilly; Novartis; Ono Pharmaceutical; Shire; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Shire
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Shire (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
David Malka
Honoraria - Amgen; Bayer; HalioDx; Merck Serono; Pierre Fabre; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; Baxalta; Bayer; HalioDx; Incyte; Merck Serono; MSD; Roche; Sanofi; SERVIER
Travel, Accommodations, Expenses - Amgen; Bayer; Merck Serono; Roche; Sanofi
 
Hyun Cheol Chung
Consulting or Advisory Role - Bristol-Myers Squibb; Celltrion; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical
 
Adnan Nagrial
No Relationships to Disclose
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Genentech/Roche; Target Pharmasolutions; Target Pharmasolutions (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Tekmira (Inst)
 
Sarina Anne Piha-Paul
Research Funding - Abbvie (Inst); Aminex (Inst); Bayer (Inst); BlueLink (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Five Prime Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); Samumed (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); TransThera Biosciences (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)
 
Willeke Ros
No Relationships to Disclose
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
 
Kazuhiko Nakagawa
Honoraria - Astellas Pharma; AstraZeneca Japan; Bristol-Myers Squibb; CareNet; Chugai Pharma; Clinical Trial Co; Daiichi Sankyo; Hisamitsu Pharmaceutical; Kyorin; Lilly; Medical Review Co., Ltd.; Medicus Shuppan Publishers; Merck Sharp & Dohme; NANZANDO Co.,Ltd.; Nichi-iko; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Reno Medical; SymBio Pharmaceuticals; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; YODOSHA; Yomiuri Telecasting Corporation
Speakers' Bureau - Astellas Pharma; Ono Pharmaceutical; Takeda
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); Gritstone Bio (Inst); ICON Clinical Research (Inst); inVentiv Health (Inst); IQvia (Inst); Kissei Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Linical (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International Corp. (Inst); Pfizer (Inst); Quintiles Inc. (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hope S. Rugo
Research Funding - Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen; Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology; Roche/Genentech; Sanofi
 
Filippo G. De Braud
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Daiichi Sankyo; Dompè; Ignyta; Incyte; Novartis; Octimet; Pfizer; Pierre Fabre; Roche; SERVIER
Speakers' Bureau - Bristol-Myers Squibb; Menarini; MSD; Novartis; Pfizer; Roche
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Roche
 
Andrea I. Varga
Consulting or Advisory Role - Clovis Oncology
Research Funding - , Boehringer Ingelheim (Inst); , Janssen Cilag, (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Roche
 
Aaron Richard Hansen
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Merck; Pfizer
Consulting or Advisory Role - Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Merck; Novartis
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Chao Gao
Employment - Sharp & Dohme
 
Suba Krishnan
No Relationships to Disclose
 
Kevin Norwood
No Relationships to Disclose
 
Toshihiko Doi
Consulting or Advisory Role - Abbvie; Amgen; Bayer; Daiichi Sankyo; Kyowa Hakko Kirin; MSD; Novartis; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst)